Powerful statement (my emphasis)...when you consider the USD$150,000 assumption for pricing that KP suggests is conservative...
Judging from conversations we have had with a variety of Key Opinion Leaders (KOL) and physicians who treat Rett Syndrome patients, we believe Acadia’s forecast of peak sales may be conservative. A number of physicians we spoke with indicated that close to 100% of their patients would at least try trofinetide.
A De-risked bio-tech with 4X upside - Karst Peak Capital, page-5
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.27 |
Change
1.000(8.15%) |
Mkt cap ! $1.696B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.39 | $12.79 | $9.854M | 751.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2545 | $13.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.29 | 1443 | 2 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |